QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.132332v1 324/2/463    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gonzalez, N. Articles by Jensen, R. T. Search for Related Content PubMed PubMed Citation Articles by Gonzalez, N. Articles by Jensen, R. T.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Molecular Basis for Agonist Selectivity and Activation of the Orphan Bombesin Receptor Subtype 3 Receptor

Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland (N.G., S.A.M., T.N., R.T.J.); Peptide Research Laboratories, Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana (S.J.H., D.H.C.); and Angiogenesis Core Facility, National Cancer Institute, National Institute of Health, Bethesda, Maryland (S.P.-N., E.Z.)

Bombesin receptor subtype (BRS)-3, a G-protein-coupled orphan receptor, shares 51% identity with the mammalian bombesin (Bn) receptor for gastrin-releasing peptide. There is increasing interest in BRS-3 because it is important in energy metabolism, glucose control, motility, and tumor growth. BRS-3 has low affinity for all Bn-related peptides; however, recently synthetic high-affinity agonists, [D-Tyr⁶/D-Phe⁶,βAla¹¹,Phe¹³,Nle¹⁴]Bn-(6–14), were described, but they are nonselective for BRS-3 over other Bn receptors. Based on these peptides, three BRS-3-selective ligands were developed: peptide 2, [D-Tyr⁶(R)-3-amino-propionic acid¹¹,Phe¹³,Nle¹⁴]Bn(6–14); peptide 3, [D-Tyr⁶,(R)-Apa¹¹,4Cl-Phe¹³,Nle¹⁴]Bn(6–14); and peptide 4, acetyl-Phe-Trp-Ala-His-(tBzl)-piperidine-3 carboxylic acid-Gly-Arg-NH₂. Their molecular determinants of selectivity/high affinity for BRS-3 are unknown. To address this, we used a chimeric/site mutagenesis approach. Substitution of extracellular domain 2 (EC2) of BRS-3 by the comparable gastrin-releasing peptide receptor (GRPR) domain decreased 26-, 4-, and 0-fold affinity for peptides 4, 3, and 2. Substitution of EC3 decreased affinity 4-, 11-, and 0-fold affinity for peptides 2 to 4. Ten-point mutations in the EC2 and adjacent transmembrane regions (TM2) 2 and 3 of BRS-3 were made. His107 (EC2-BRS-3) for lysine (H107K) (EC2-GRPR) decreased affinity (25- and 0-fold) for peptides 4 and 1; however, it could not be activated by either peptide. Its combination with Val101 (TM2), Gly112 (EC2), and Arg127 (TM3) resulted in complete loss-of-affinity of peptide 4. Receptor-modeling showed that each of these residues face inward and are within 4 Å of the binding pocket. These results demonstrate that Val101, His107, Gly112, and Arg127 in the EC2/adjacent upper TMs of BRS-3 are critical for the high BRS3 selectivity of peptide 4. His107 in EC2 is essential for BRS-3 activation, suggesting amino-aromatic ligand/receptor interactions with peptide 4 are critical for both binding and activation. Furthermore, these result demonstrate that even though these three BRS-3-selective agonists were developed from the same template peptide, [D-Phe⁶,βAla¹¹,Phe¹³,Nle¹⁴]Bn-(6–14), their molecular determinants of selectivity/high affinity varied considerably.

Address correspondence to: Dr. Robert T. Jensen, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Heath, Building 10, Room 9C-103, 10 Center Dr. MSC 1804, Bethesda, MD 20892-1804. E-mail: robertj{at}bdg10.niddk.nih.gov